B7-H3 expression associates with tumor invasion and patient’s poor survival in human esophageal cancer

American Journal of Translational Research

Volumn 7, Issue 12, 2015, Pages 2646-2660

  Chen, Lu Jun ^a,b   Chen, Jun ^c   Xu, Bin ^a,b   Wang, Qi ^a,b   Zhou, Wei ^d   Zhang, Guang Bo ^e   Sun, Jing ^e   Shi, Liang Rong ^a,b   Pei, Hong Lei ^c   Wu, Chang Ping ^a,b   Jiang, Jing Ting ^a,b  

^a Department of Tumor Biological Treatment ^*  (China)

^b Jiangsu Engineering Research Center for Tumor Immunotherapy   (China)

^c THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^d SOOCHOW UNIVERSITY   (China)

^e THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

B7 H3; Esophageal cancer; Infiltrating CD3+T cells; Prognosis; RNA interference

Indexed keywords

B7 H3 PROTEIN; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER SURVIVAL; CELL MIGRATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ESOPHAGUS CANCER; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR INVASION; WESTERN BLOTTING;

EID: 84956921104     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Schottenfeld D. Epidemiology of cancer of the esophagus. Semin Oncol 1984; 11: 92-100.
2. Yang CS. Research on esophageal cancer in China: a review. Cancer Res 1980; 40: 2633-2644.
3. Stoner GD and Gupta A. Etiology and chemo­prevention of esophageal squamous cell carci­noma. Carcinogenesis 2001; 22: 1737-1746.
4. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
5. Chen L, Luo G, Tan Y, Wei J, Wu C, Zheng L, Zhang X and Xu N. Immunolocalisation of tis­sue factor in esophageal cancer is correlated with intratumoral angiogenesis and prognosis of the patient. Acta Histochem 2010; 112: 233-239.
6. Stoner GD, Wang LS and Chen T. Chemopre­vention of esophageal squamous cell carcino­ma. Toxicol Appl Pharmacol 2007; 224: 337-349.
7. Enzinger PC and Mayer RJ. Esophageal cancer. N Engl J Med 2003; 349: 2241-2252.
8. Sharpe AH and Freeman GJ. The B7-CD28 su­perfamily. Nat Rev Immunol 2002; 2: 116-126.
9. Lu B, Chen L, Liu L, Zhu Y, Wu C, Jiang J and Zhang X. T-cell-mediated tumor immune sur­veillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointes­tinal tract. Immunol Res 2011; 50: 269-275.
10. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C and Ribas A. PD-1 blockade induces respons­es by inhibiting adaptive immune resistance. Nature 2014; 515: 568-571.
11. Seliger B and Quandt D. The expression, func­tion, and clinical relevance of B7 family mem­bers in cancer. Cancer Immunol Immunother 2012; 61: 1327-1341.
12. Zou W and Chen L. Inhibitory B7-family mole­cules in the tumour microenvironment. Nat Rev Immunol 2008; 8: 467-477.
13. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM and Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
14. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS and Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody MPD­L3280A in cancer patients. Nature 2014; 515: 563-567.
15. Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG and Xu N. Immunohistochemical localization of pro­grammed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 2006; 108: 19-24.
16. Chen L, Sun J, Wu H, Zhou S, Tan Y, Tan M, Shan B, Lu B and Zhang X. B7-H4 expression associates with cancer progression and pre­dicts patient’s survival in human esophageal squamous cell carcinoma. Cancer Immunol Immunother 2011; 60: 1047-1055.
17. Sun J, Chen L, Zhang G, Jiang J, Zhu M, Tan Y, Wang H, Lu B and Zhang X. Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunol Immunother 2010; 59: 1163-1171.
18. Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, Dong H, Sica GL, Zhu G, Tamada K and Chen L. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2001; 2: 269-274.
19. Steinberger P, Majdic O, Derdak SV, Pfistershammer K, Kirchberger S, Klauser C, Zlabinger G, Pickl WF, Stockl J and Knapp W. Molecular characterization of human 4Ig-B7-H3, a mem­ber of the B7 family with four Ig-like domains. J Immunol 2004; 172: 2352-2359.
20. Loos M, Hedderich DM, Friess H and Kleeff J. B7-H3 and its role in antitumor immunity. Clin Dev Immunol 2010; 2010: 683875.
21. Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frilgoa X, Inman BA, Krambeck AE, McKenney ME, Karnes RJ, Blute ML, Cheville JC, Sebo TJ and Kwon ED. B7-h3 ligand expression by prostate cancer: a novel marker of prognosis and poten­tial target for therapy. Cancer Res 2007; 67: 7893-7900.
22. Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, Scardino PT, Shar­ma P and Allison JP. B7-H3 and B7x are highly expressed in human prostate cancer and as­sociated with disease spread and poor out­come. Proc Natl Acad Sci U S A 2007; 104: 19458-19463.
23. Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, Thompson RH, Boorjian SA, Dong H, Leibovich BC, Blute ML and Kwon ED. Tumor cell and tumor vasculature expres­sion of B7-H3 predict survival in clear cell re­nal cell carcinoma. Clin Cancer Res 2008; 14: 5150-5157.
24. Zang X, Sullivan PS, Soslow RA, Waitz R, Re­uter VE, Wilton A, Thaler HT, Arul M, Slovin SF, Wei J, Spriggs DR, Dupont J and Allison JP. Tu­mor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol 2010; 23: 1104-1112.
25. Sun TW, Gao Q, Qiu SJ, Zhou J, Wang XY, Yi Y, Shi JY, Xu YF, Shi YH, Song K, Xiao YS and Fan J. B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor ag­gressiveness and postoperative recurrence. Cancer Immunol Immunother 2012; 61: 2171-2182.
26. Tekle C, Nygren MK, Chen YW, Dybsjord I, Nesland JM, Maelandsmo GM and Fodstad O. B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes. Int J Cancer 2012; 130: 2282-90.
27. Yuan H, Wei X, Zhang G, Li C, Zhang X and Hou J. B7-H3 over expression in prostate cancer promotes tumor cell progression. J Urol 2011; 186: 1093-1099.
28. Zhao X, Li DC, Zhu XG, Gan WJ, Li Z, Xiong F, Zhang ZX, Zhang GB, Zhang XG and Zhao H. B7-H3 overexpression in pancreatic cancer promotes tumor progression. Int J Mol Med 2013; 31: 283-291.
29. Chen LJ, Sun J, Wu HY, Zhou SM, Tan Y, Tan M, Shan BE, Lu BF and Zhang XG. B7-H4 expres­sion associates with cancer progression and predicts patient’s survival in human esopha­geal squamous cell carcinoma. Cancer Immu­nol Immunother 2011; 60: 1047-1055.
30. Chen L, Di D, Luo G, Zheng L, Tan Y, Zhang X and Xu N. Immunochemical staining of MT2-MMP correlates positively to angiogenesis of human esophageal cancer. Anticancer Res 2010; 30: 4363-4368.
31. Chen LJ, Zheng X, Shen YP, Zhu YB, Li Q, Chen J, Xia R, Zhou SM, Wu CP, Zhang XG, Lu BF and Jiang JT. Higher numbers of T-bet(+) intratu­moral lymphoid cells correlate with better sur­vival in gastric cancer. Cancer Immunol Immu­nother 2013; 62: 553-561.
32. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, Wu WZ, Wang L, Tang ZY and Sun HC. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative re­section of hepatocellular carcinoma. J Clin On­col 2008; 26: 2707-2716.
33. Geng Y, Wang H, Lu C, Li Q, Xu B, Jiang J and Wu C. Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3 Tregs in gastric can­cer and its clinical significance. Int J Clin Oncol 2015; 20: 273-81.
34. Katayama A, Takahara M, Kishibe K, Nagato T, Kunibe I, Katada A, Hayashi T and Harabuchi Y. Expression of B7-H3 in hypopharyngeal squa­ mous cell carcinoma as a predictive indicator for tumor metastasis and prognosis. Int J On­col 2011; 38: 1219-1226.
35. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH and Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-1964.
36. Hashiguchi M, Kobori H, Ritprajak P, Kamimura Y, Kozono H and Azuma M. Triggering recep­tor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and en­hances T cell responses. Proc Natl Acad Sci U S A 2008; 105: 10495-10500.
37. Wang F, Wang G, Liu T, Yu G, Zhang G and Luan X. B7-H3 was highly expressed in human pri­mary hepatocellular carcinoma and promoted tumor progression. Cancer Invest 2014; 32: 262-271.